Patents by Inventor Francesca Bersani

Francesca Bersani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETING HUMAN SATELLITE II (HSATII)
    Publication number: 20200017856
    Abstract: Methods for treating cancer, e.g., cancer of epithelial origin, by specifically targeting human satellite II (HSATII) using sequence specific agents such as oligonucleotides.
    Type: Application
    Filed: April 24, 2019
    Publication date: January 16, 2020
    Inventors: David T. Ting, Daniel A. Haber, Shyamala Maheswaran, Francesca Bersani, Anders M. Naar, Mihir Shivadatta Rajurkar, Sakari Kauppinen, Andreas Petri
  • Targeting human satellite II (HSATII)
    Patent number: 10301624
    Abstract: Methods for treating cancer, e.g., cancer of epithelial origin, by specifically targeting human satellite II (HSATII) using sequence specific agents such as oligonucleotides. As shown herein, the hetero chromatic HSATII satellite repeat is silenced in normal cells, but massively over expressed in epithelial cancers and in cancer cell lines when grown as xenografts or in 3D culture. Induction of HSATII RNA, either in xenografts or using in vitro reconstitution models, suggests the appearance of complementary DNA intermediates.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: May 28, 2019
    Assignees: The General Hospital Corporation, Aalborg University
    Inventors: David T. Ting, Daniel A. Haber, Shyamala Maheswaran, Francesca Bersani, Anders M. Naar, Mihir Shivadatta Rajurkar, Sakari Kauppinen, Andreas Petri
  • TARGETING HUMAN SATELLITE II (HSATII)
    Publication number: 20170198288
    Abstract: Methods for treating cancer, e.g., cancer of epithelial origin, by specifically targeting human satellite II (HSATII) using sequence specific agents such as oligonucleotides. As shown herein, the hetero chromatic HSATII satellite repeat is silenced in normal cells, but massively over expressed in epithelial cancers and in cancer cell lines when grown as xenografts or in 3D culture. Induction of HSATII RNA, either in xenografts or using in vitro reconstitution models, suggests the appearance of complementary DNA intermediates.
    Type: Application
    Filed: June 25, 2015
    Publication date: July 13, 2017
    Inventors: David T. Ting, Daniel A. Haber, Shyamala Maheswaran, Francesca Bersani, Anders M. Naar, Mihir Shivadatta Rajurkar